SCHEMBL25859539

SCHEMBL25859539

Brc1nnc(N2CCOCC2)s1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 8/20 0.42
SMN1; SMN2 Q16637 8/20 0.42
NPC1 O15118 6/20 0.42
MAPT P10636 5/20 0.41
LMNA P02545 2/20 0.41
MAPK1 P28482 2/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
PIK3CD O00329 2/20 0.40
PIK3CA P42336 2/20 0.40
PIK3CB P42338 2/20 0.40
ALOX15 P16050 2/20 0.40
TP53 P04637 2/20 0.39
PIK3CG P48736 1/20 0.39
USP2 O75604 1/20 0.39
PKM P14618 1/20 0.39
AR P10275 3/20 0.39
HTT P42858 1/20 0.38
GAA P10253 4/20 0.38
ALDH1A1 P00352 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21725122 0.80 ALDH1A1 (0.57) RAB9ASMN1; SMN2NPC1MAPTLMNA
SCHEMBL21737951 0.78 ALDH1A1 (0.61) RAB9ASMN1; SMN2NPC1MAPTMAPK1
SCHEMBL13428031 0.78 AR (0.44) RAB9ASMN1; SMN2NPC1MAPTLMNA
SCHEMBL5456183 0.78 ALDH1A1 (0.66) RAB9ASMN1; SMN2NPC1MAPTLMNA
SCHEMBL12263529 0.78 PIK3CD (0.46) RAB9ASMN1; SMN2NPC1MAPTLMNA
SCHEMBL21737993 0.77 GAA (0.38) MAPK1GAAALDH1A1HSD17B10
SCHEMBL8771166 0.76 SMN1; SMN2 (0.40) RAB9ASMN1; SMN2NPC1MAPTLMNA
SCHEMBL21725030 0.76 CYP11B1 (0.39) RAB9ASMN1; SMN2NPC1MAPK1GAA
SCHEMBL31492979 0.75 TDP1 (0.43) RAB9ASMN1; SMN2NPC1MAPK1KMT2A
SCHEMBL25858317 0.74 HRH3 (0.38) RAB9ASMN1; SMN2NPC1MAPK1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260028365-A1 TYROSINE KINASE 2 INHIBITORS AND USES THEREOF BIOGEN MA INC (US) 2026-01-29 US disclosed
CN-119894879-A Tyrosine kinase 2 inhibitors and uses thereof 渤健马萨诸塞州股份有限公司 2025-04-25 CN disclosed
US-11702414-B2 Thiadiazole IRAK4 inhibitors GILEAD SCIENCES, INC. (US) 2023-07-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11702414-B2 Thiadiazole IRAK4 inhibitors IRAK4, IRAK3, IRAK1 RAB9A 3483/4885SMN1; SMN2 1294/4885NPC1 1421/4885
US-20260028365-A1 TYROSINE KINASE 2 INHIBITORS AND USES THEREOF TYK2, ERBB2, ROS1 RAB9A 1942/4885SMN1; SMN2 1972/4885NPC1 3166/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.